Home Featured Page 259

Featured

Latest

January 2025 Psychedelic Paten Update: Lykos’ New Continuation Applications; Ambio Files on Ibogaine & Magnesium

Microdosing, Psychedelic Science, and the Future of Mental Health with Paul Austin

A Crucible of Academia, Psychedelics, and Religion: Psychedelic Intersections 2025 at The Harvard Divinity School

UK Psychedelic Research Hindered by Red Tape, Experts Tell Lawmakers in Parliamentary Report

MDMA for Active-Duty Troops: Aaron Wolfgang on DoD’s Unprecedented Study

atai Life Sciences Announces the Closing of its $157 Million Series...

Cybin Inc. Announces Uplisting to OTCQB Venture Market

Red Light Holland’s iMicro Digital Care App Launches Virtual Telecounseling with...

Lobe Sciences Appoints NFL Alumni Association President, Bart Oates Esq. to...

Entheon Biomedical Announces Nancy Maher, Special Advisor of Data Science and...

Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonists Show Significant Reduction in...

BetterLife Engages Eurofins CDMO for Next Generation Psychedelic TD-0148A Manufacturing

MINDCURE Announces Manufacturing of Synthetic Ibogaine to be Used in Company’s...

Nova Mentis Launches Autism Microbiome Study in the United States

Awakn Announces Exclusive License Deal with the University of Exeter to...

1...258259260...281 Page 259 of 281

January 2025 Psychedelic Paten Update: Lykos’ New Continuation Applications; Ambio Files...

Microdosing, Psychedelic Science, and the Future of Mental Health with Paul...

A Crucible of Academia, Psychedelics, and Religion: Psychedelic Intersections 2025 at...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.